Cargando…

Relevance of Breast Cancer Resistance Protein to Pharmacokinetics of Florfenicol in Chickens: A Perspective from In Vivo and In Vitro Studies

Florfenicol (FFC) is a valuable synthetic fluorinated derivative of thiamphenicol widely used to treat infectious diseases in food animals. The aims of the study were to investigate whether FFC is a substrate for the breast cancer resistance protein (BCRP) and whether the transporter influences oral...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yang, Guo, Li, Zloh, Mire, Zhang, Yujuan, Huang, Jinhu, Wang, Liping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214120/
https://www.ncbi.nlm.nih.gov/pubmed/30326566
http://dx.doi.org/10.3390/ijms19103165
_version_ 1783367928966545408
author Liu, Yang
Guo, Li
Zloh, Mire
Zhang, Yujuan
Huang, Jinhu
Wang, Liping
author_facet Liu, Yang
Guo, Li
Zloh, Mire
Zhang, Yujuan
Huang, Jinhu
Wang, Liping
author_sort Liu, Yang
collection PubMed
description Florfenicol (FFC) is a valuable synthetic fluorinated derivative of thiamphenicol widely used to treat infectious diseases in food animals. The aims of the study were to investigate whether FFC is a substrate for the breast cancer resistance protein (BCRP) and whether the transporter influences oral availability of FFC. In vitro transport assays using MDCK-chAbcg2 cells were conducted to assess chicken BCRP-mediated transport of FFC, while in vivo pharmacokinetic experiments with single or combined BCRP inhibitor gefitinib were employed to study the role of BCRP in oral FFC disposition. According to U.S. Food and Drug Administration (FDA) criteria, FFC was found to be a potential BCRP substrate due to the net efflux ratio being over 2.0 (2.37) in MDCK cells stably transfected with chicken BCRP and the efflux completely reversed by a BCRP inhibitor (Gefitinib). The molecular docking results indicated that florfenicol can form favorable interactions with the binding pocket of homology modeled chicken BCRP. Pharmacokinetic studies of FFC in different aged broilers with different expression levels of BCRP showed that higher BCRP expression would cause a lower Area Under Curve (AUC) and a higher clearance of FFC. In addition, more extensive absorption of florfenicol after the co-administration with gefitinib (a BCRP inhibitor) was observed. The overall results demonstrated that florfenicol is a substrate of the chicken breast cancer resistant protein which in turn affects its pharmacokinetic behavior.
format Online
Article
Text
id pubmed-6214120
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62141202018-11-14 Relevance of Breast Cancer Resistance Protein to Pharmacokinetics of Florfenicol in Chickens: A Perspective from In Vivo and In Vitro Studies Liu, Yang Guo, Li Zloh, Mire Zhang, Yujuan Huang, Jinhu Wang, Liping Int J Mol Sci Article Florfenicol (FFC) is a valuable synthetic fluorinated derivative of thiamphenicol widely used to treat infectious diseases in food animals. The aims of the study were to investigate whether FFC is a substrate for the breast cancer resistance protein (BCRP) and whether the transporter influences oral availability of FFC. In vitro transport assays using MDCK-chAbcg2 cells were conducted to assess chicken BCRP-mediated transport of FFC, while in vivo pharmacokinetic experiments with single or combined BCRP inhibitor gefitinib were employed to study the role of BCRP in oral FFC disposition. According to U.S. Food and Drug Administration (FDA) criteria, FFC was found to be a potential BCRP substrate due to the net efflux ratio being over 2.0 (2.37) in MDCK cells stably transfected with chicken BCRP and the efflux completely reversed by a BCRP inhibitor (Gefitinib). The molecular docking results indicated that florfenicol can form favorable interactions with the binding pocket of homology modeled chicken BCRP. Pharmacokinetic studies of FFC in different aged broilers with different expression levels of BCRP showed that higher BCRP expression would cause a lower Area Under Curve (AUC) and a higher clearance of FFC. In addition, more extensive absorption of florfenicol after the co-administration with gefitinib (a BCRP inhibitor) was observed. The overall results demonstrated that florfenicol is a substrate of the chicken breast cancer resistant protein which in turn affects its pharmacokinetic behavior. MDPI 2018-10-15 /pmc/articles/PMC6214120/ /pubmed/30326566 http://dx.doi.org/10.3390/ijms19103165 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Liu, Yang
Guo, Li
Zloh, Mire
Zhang, Yujuan
Huang, Jinhu
Wang, Liping
Relevance of Breast Cancer Resistance Protein to Pharmacokinetics of Florfenicol in Chickens: A Perspective from In Vivo and In Vitro Studies
title Relevance of Breast Cancer Resistance Protein to Pharmacokinetics of Florfenicol in Chickens: A Perspective from In Vivo and In Vitro Studies
title_full Relevance of Breast Cancer Resistance Protein to Pharmacokinetics of Florfenicol in Chickens: A Perspective from In Vivo and In Vitro Studies
title_fullStr Relevance of Breast Cancer Resistance Protein to Pharmacokinetics of Florfenicol in Chickens: A Perspective from In Vivo and In Vitro Studies
title_full_unstemmed Relevance of Breast Cancer Resistance Protein to Pharmacokinetics of Florfenicol in Chickens: A Perspective from In Vivo and In Vitro Studies
title_short Relevance of Breast Cancer Resistance Protein to Pharmacokinetics of Florfenicol in Chickens: A Perspective from In Vivo and In Vitro Studies
title_sort relevance of breast cancer resistance protein to pharmacokinetics of florfenicol in chickens: a perspective from in vivo and in vitro studies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214120/
https://www.ncbi.nlm.nih.gov/pubmed/30326566
http://dx.doi.org/10.3390/ijms19103165
work_keys_str_mv AT liuyang relevanceofbreastcancerresistanceproteintopharmacokineticsofflorfenicolinchickensaperspectivefrominvivoandinvitrostudies
AT guoli relevanceofbreastcancerresistanceproteintopharmacokineticsofflorfenicolinchickensaperspectivefrominvivoandinvitrostudies
AT zlohmire relevanceofbreastcancerresistanceproteintopharmacokineticsofflorfenicolinchickensaperspectivefrominvivoandinvitrostudies
AT zhangyujuan relevanceofbreastcancerresistanceproteintopharmacokineticsofflorfenicolinchickensaperspectivefrominvivoandinvitrostudies
AT huangjinhu relevanceofbreastcancerresistanceproteintopharmacokineticsofflorfenicolinchickensaperspectivefrominvivoandinvitrostudies
AT wangliping relevanceofbreastcancerresistanceproteintopharmacokineticsofflorfenicolinchickensaperspectivefrominvivoandinvitrostudies